Dr. Reddy’s shares fell after Canada’s drug regulator sought clarifications on its Semaglutide injection, affecting supplier Shaily Engineering Plastics’ outlook.

• Dr. Reddy’s received a Notice of Non-Compliance from Canada for its Semaglutide application, requiring additional data and clarifications soon.
• Shaily’s shares plunged as demand concerns arose; it produces Semaglutide pens and recently expanded capacity by 25 million pens yearly.
• Analysts expect short-term pressure but remain bullish, citing global Semaglutide market growth to $93.6 billion by 2035, driven by obesity treatment.